Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Scientists Engineer New Cancer Immunotherapy to Train Immune System in Cancer Fight


A groundbreaking new type of cancer immunotherapy developed at the Icahn School of Medicine at Mount Sinai trains the innate immune system to help it eliminate tumor cells through the use of nanobiologics, tiny materials bioengineered from natural molecules that are paired with a therapeutic component, according to a study published in Cell in October.

This nanobiologic immunotherapy targets the bone marrow, where part of the immune system is formed, and activates a process called trained immunity. This process reprograms bone marrow progenitor cells to produce “trained” innate immune cells that halt the growth of cancer, which is normally able to protect itself from the immune system with the help of other types of cells, called immunosuppressive cells.

This work for the first time demonstrates that trained immunity can be successfully and safely induced for the treatment of cancer. The research was performed in animal models, including a mouse model with melanoma, and the researchers said it is being developed for clinical testing.

Immunotherapies that are already part of standard cancer care, such as the drug that eliminated former President Jimmy Carter’s metastatic melanoma, are also able to unmask cancer to the immune system, but they have limitations. The type of immunotherapy used for former President Carter, called a checkpoint inhibitor, fully benefits only a small number of patients and can have severe side effects.

Findings from this research demonstrate that the nanobiologic immunotherapy’s trained immunity approach could be used as a stand-alone anti-cancer therapy, potentially with fewer adverse reactions, or in conjunction with checkpoint inhibitor drugs, the scientists say.

“Not only have we observed very strong anti-cancer effects of our nanobiologic immunotherapy,” said lead author Willem J. Mulder, PhD, Professor of Diagnostic, Molecular and Interventional Radiology and member of the Biomedical Engineering and Imaging Institute at the Icahn School of Medicine at Mount Sinai. “The work involves the development and preclinical evaluation of a novel immunotherapy based on highly biocompatible nanomaterials called nanobiologics. Our study is a significant advancement for both trained immunity and cancer treatment, with real potential to move quickly into use in patients.”

This research was part of a large collaboration between the Icahn School of Medicine and multiple other institutes and universities in the United States and Europe.

“This study is a game changer in the field of immunotherapy,” said Zahi A. Fayad, PhD, Director of the Biomedical Engineering and Imaging Institute, and another author on the paper. “We are continuing the exploration of the technology at Mount Sinai and with our international collaborators.”

About the Mount Sinai Health System

The Mount Sinai Health System is New York City’s largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care—from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report’s “Honor Roll” of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty and our physicians in the top 1% of all physicians nationally by U.S. News & World Report.

For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

Share article on social media or email:

David Pyrce Joins DevaCell as Chief Executive Officer


DevaCell Inc. today announced that David Pyrce has joined the company as Chief Executive Officer. Mr. Pyrce brings over 30 years of biotechnology and pharmaceutical industry leadership, together with deep Wall Street experience and will lead all aspects of DevaCell’s growth strategy focused on the development of ONCoatTM-enabled, synthetic vector-based therapeutics across three key market segments – oncolytic viral therapy, vaccines, and gene therapy/gene editing.

“We are very pleased to welcome David into leadership of the DevaCell team,” said Larry Stambaugh, Chairman of DevaCell. “David’s extensive biotech and pharma drug development expertise, and proven executive management skills, will significantly accelerate DevaCell at a time when management is focusing on transitioning the company’s novel synthetic vector-based therapeutics into the clinic by mid-year 2021.” Mr. Stambaugh continued, “In addition, David’s extensive long-term relationships on Wall Street, as well as the biotech and pharma industries, will be key to securing strategic capital partners to fund preclinical and clinical development activities, together with establishing biotech and pharma collaborators, that will create additional clinical programs using DevaCell’s pipeline of next generation therapeutics.”

Mr. Pyrce is a biotech, pharma and Wall Street veteran, mostly recently serving as Senior Vice President, Strategy, Innovations and Chief Commercial Officer of NantKwest, a cell therapy company. Prior to NantKwest, David was the Founder, Chairman and CEO of Genomic Principles, a molecular diagnostics and neoantigen-based therapeutics company. Earlier in his career, David held executive management positions in business development, marketing and sales for BioMarin Pharmaceuticals/Glyko, Glaxo/SmithKline Beecham, and Baxter Healthcare. On Wall Street, David was the Founder, CEO and Managing General Partner of Bear Creek Capital Management and Bear Creek Capital Partners, a healthcare-focused hedge fund. David was also Senior Sell-Side Analyst at Wells Fargo Securities. David received his MBA from the Stuart School at the Illinois Institute of Technology in Chicago, and has dual bachelor degrees in Chemistry and Biology from Northern Illinois University.

Inanc Ortac, Ph.D, Founder and Chief Scientific Officer of DevaCell commented, “It is an honor, especially at our current pivotal stage of moving into clinical programs, to have David bring his deep skill set, from startup entrepreneur to successfully completing multiple IPOs and help to translate our platform technology to a truly transformative product pipeline of high impact therapeutics,” Dr. Ortac continued, “The innovative science and development of DevaCell’s platform technology from discovery to preclinical development over the past several years has positioned the company very well to become a leader in next-generation therapeutics. We welcome David to the DevaCell team.”

Mr. Pyrce commented, “I take great pride in being trusted with the role of CEO at DevaCell. As the coronavirus pandemic has shown, the need for innovative, next generation therapies has never been greater and I truly believe that DevaCell’s synthetic vector-based therapeutics platform is truly game changing, offering the potential to deliver highly effective therapeutics on a systemic basis, while also enabling repeat administration, something that has not been previously available.” Mr. Pyrce continued, “With a focused strategy to transition the company’s first therapeutics program into human clinical trials in 2021, the company is at a key inflection point, and I’m honored to be given the opportunity to help bring novel, high-impact therapeutics to patients as quickly as possible.”

About DevaCell Inc

DevaCell is a San Diego based synthetic vector-based therapeutics firm focused on developing a product pipeline of best-in-class therapeutics across three key segments: Oncolytic virus therapies, vaccines, and gene therapy/gene editing applications. DevaCell’s DEVA (designer encapsulated viral assembly) is the foundational innovation for the company’s transformative nanoparticle-based, ONCoatTM synthetic vector platform technology, which is enabling the development of a portfolio of innovative therapeutic products candidates. The company’s lead oncolytic virus program includes product candidates that have been engineered to express multiple transgenes that include novel combinations of immunomodulators, checkpoint inhibitors, and ligands for T-cell costimulatory or coinhibitory receptors and metabolic modifiers. In preclinical development is an infectious disease vaccine for COVID-19, and in discovery research are applications in gene therapy/gene editing.

Contact

DevaCell Inc

David Pyrce

951-551-0949

dpyrce@devacell.com

DevaCell.com

Share article on social media or email:

Move United Offers Over 1,000 Virtual Programs During Coronavirus Pandemic


Adaptive Athlete Logan Aldridge lifting weights

Logan Aldridge, from the Adaptive Training Academy, led some of the AdaptAtHome virtual workouts.

This isn’t the time for people to be sidelined, said Move United Executive Director Glenn Merry

As an adaptive sports organization, Move United knows all about adapting, so the organization was quickly able to pivot its programs and activities online when the Coronavirus pandemic hit the nation back in March 2020. In the last six months, the national nonprofit organization has offered over 1,000 virtual programs to individuals with physical disabilities to encourage health and fitness.

Move United, the national leader in community adaptive sports, focuses on providing opportunities for individuals with disabilities to develop independence, confidence, and fitness through participation in community sports, recreation, and educational programs. Through its activities and its network of nearly 200 member organizations across the country, these past several months would normally be filled with clinics, practices, competitions, regional games, and other adaptive sports programming. But COVID-19 altered many of those activities.

According the American Psychological Association, emerging research on COVID-19 shows that the coronavirus pandemic has increased psychological distress particularly among people with disabilities. The pandemic not only impacted access to local sports, fitness, and wellness programs in communities across the country, but the physical distancing guidelines also led to higher levels of social isolation. “This isn’t the time for people to be sidelined,” said Move United Executive Director Glenn Merry. “Particularly during trying times like these, we know how important it is to maintain physical and mental health. These reasons immediately drove our attention to host sports, fitness, and wellness activities across digital platforms with our #AdaptAtHome program.”

The 1,000+ live and on-demand sessions hosted by Move United, its member network, and partners had over 250,000 engagements since April 1. Participants hailed from all 50 states, the District of Columbia, and Puerto Rico. By offering programming virtually, the organization was able to reach beyond its existing network. “We know not everyone has access to an adaptive sports program in their community,” Merry said. “By offering virtual programs, we are changing what people experience as barriers to access.”

As another way to support individuals who may not have access to fitness equipment, Move United created an #AdaptAtHome Fitness Kit, which includes a ball, exercise band, cordless jump rope, and other resources so individuals can exercise wherever they are. By December, over 1,500+ fitness kits will be distributed free of charge. Live programs and recorded fitness sessions also showcase how each item can be utilized.

Participants in the virtual programs included adaptive athletes, disabled veterans, youth and adults with disabilities, adaptive sports coaches, program volunteers and staff, health providers, and others. 90% of participants agreed that the programming helps increase the overall level of physical fitness and 97% agree participating in virtual adaptive sports improves their mood and mental health. “We know the power of sports. Sports make us stronger physically, mentally, and emotionally,” said Merry.

60 different organizations have been part of the #AdaptAtHome initiative, providing online programming in 45 different sports. The top offerings have included strength and conditioning, yoga, cycling, dance, and fitness. The virtual programs are offered free of charge to all participants. Move United has curated a resource library through the #AdaptAtHome page on its website. To learn more, visit moveunitedsport.org/adaptathome.

Share article on social media or email:

Partners Pharmacy Releases Findings of Independent Study Evaluating Impact of APS Dispensing Technology


Partners Pharmacy is proud to release the findings of a recent independent study which evaluates the impact of Partners’ APS remote medication dispensing technology designed for the post-acute community. Partners’ APS brings the pharmacy into the facility reducing outside interaction between pharmacy couriers and nursing home staff. A key factor as facilities continue to face the impacts of the COVID-19 pandemic. The study, conducted over an 18- month period which involved 52 nursing facilities was validated by Centric Consulting, a national business, technology and digital consulting firm. Performance elements included customer feedback and benefits, including quality, time savings, workflow savings, ease of use and adoption, space savings, and reduction in drug waste. Michelle Brown of Centric’s Operational Excellence Practice led the validation and verification.

Brown reviewed study data, derived calculations and metrics. She also conducted interviews of the individual(s) who led the field study and built the measurement system and output metrics. Centric Consulting concluded that the field study approach was sound and the resulting key metrics and benefits were calculated in an appropriate manner, and they accurately reflect the results of the data collected.

Timothy Dimond of Centric Consulting stated, “Centric Consulting has concluded that the field study approach was sound and the resulting key metrics and benefits were calculated in an appropriate manner, and they accurately reflect the results of the data collected. Centric was proud to be part of this validation study of Partners APS and its recognized benefits to the post-acute and senior living populations.

Anthony Spero, COO of Partners Pharmacy was very pleased with the confirmation of the data collected for the white paper study. Mr. Spero states, “The next generation of Passport takes the efficiency of our AP Passport technology to the next level. Partners Advanced Pharmacy Solutions, or APS, is an integrated multi dose dispensing system made especially for long-term care. This ecosystem of four units combine in an easy-to-use solution ideal for today’s time-strapped nursing staff especially during this pandemic when we know facilities are managing staffing challenges along with the challenges of limiting outside interactions. The new software is enhanced for ease of use and interacts with the electronic health record. The white paper study validates the features and benefits as a key solution in long term care settings.”

To access the Partners APS white paper study conducted by Centric Consulting, please visit http://www.PartnersAPS.com.

About Partners Pharmacy – Partners Pharmacy is one of the largest long-term care pharmacy providers in the U.S. Each regional Partners location provides the same unmatched personalized service through the combined resources of local teams and expanding national resources. Partners collaborates with the communities it serves to improve outcomes, reduce costs and increase operational efficiencies that permit more time for direct patient care. Performance elements and manufacturing of Partners APS are developed by American company Tech Pharmacy Services in Houston, Texas. Tech Pharmacy Services designs, develops, implements and services technology based solutions to meet 21st century pharmaceutical service needs. For more information about Partners APS, visit

http://www.PartnersAPS.com or email info@PartnersAPS.com.

Share article on social media or email:

Dialysis Care Center (DCC) First to Introduce Baxter’s Novel Theranova Dialyzer to U.S. Market


Dialysis Care Center Evergreen Park, IL Ribbon Cutting

We are excited that through our continued relationship with Baxter, they have partnered with DCC to be the first center to introduce their new product to the U.S. market.

On Monday, October 19th Dialysis Care Center (DCC), a rapidly growing dialysis provider, celebrated their new state-of-the-art, in-center located at 9834 South Kedzie Avenue in Evergreen Park, Illinois with a ribbon-cutting ceremony. Attended by DCC staff, patients, and Baxter Healthcare representatives, the occasion not only marks a milestone in DCC’s tremendous growth throughout 2020 and commitment to providing patient-centric care to those with end-stage chronic kidney disease in the Evergreen Park community, it also celebrated their continued relationship with Baxter Healthcare.

DCC Evergreen Park is the first location in the U.S. where Theranova, Baxter Healthcare’s novel dialyzer designed to deliver expanded hemodialysis (HDx) therapy, is being used for patient care. The Theranova dialyzer’s unique membrane design offers a filtration profile that more closely mimics that of the natural kidney and can be used with existing hemodialysis machines.1,2 Multiple patients are now on therapy.

According to Baxter, “We are doing everything we can in the U.S. to ensure healthcare providers can realize the full value of HDx therapy enabled by Theranova for their patients on HD,” said Gavin Campbell, general manager of Baxter’s U.S. Renal Care business. “Similarly, we know Dialysis Care Center understands the opportunity to bring its patients a promising alternative in Theranova to what is currently available with standard HD treatment.”

“Dialysis Care Center is always interested in partnering with companies that are finding innovative ways to enhance the quality of dialysis care that we provide to our patients. We are excited that through our continued relationship with Baxter, they have partnered with DCC to be the first center to introduce their new product to the U.S. market.” stated Babajide Salako, MD, Chief Executive Officer, Dialysis Care Center.

1 Kirsch AH, et al. Performance of hemodialysis with novel medium cut-off dialyzers. Nephrol Dial Transplant. 2017; 32:165-172.

2 Zweigart C, et al. Medium cut-off membranes – closer to the natural kidney removal function. Int J Artif Organs. 2017; 40(7):328-334

Share article on social media or email:

Healthfuse CEO to Moderate Live Becker’s Hospital Review Panel with Leading Revenue Cycle Management Organizations


Healthfuse, the industry leader in managing and sourcing revenue cycle vendors for hospitals and health systems, announced today that its President and CEO Nick Fricano will moderate a Becker’s Hospital Review live panel on Tuesday, November 17th, 2020 at 1:00 pm CST.

Fricano will lead the discussion around the COVID-19 pandemic and how it created an overnight financial crisis for hospitals nationwide, forcing hospital revenue cycle leaders to make tough choices, such as redeploying staff, sourcing new vendors and implementing new self-pay billing and collections processes. RCM leaders will draw upon their experiences to provide effective hospital vendor management strategies that can help hospitals financially recover from the pandemic, and better position their organizations as the country looks to the future.

Featured panelists include:

Key takeaways from the panel will be:

  • Vendor trends and the effects the pandemic induced regionally and nationally
  • Lessons from front-line revenue cycle leaders
  • Proactive, growth-minded vendor management strategies

“COVID-19 has been a catalyst for significant change in the healthcare financial sector. Revenue cycle vendors have pivoted to help hospitals quickly adapt and respond, protecting both the patient financial experience and the revenue stream. I look forward to having a lively discussion with these RCM leaders about their strategies for handling the crisis and tips for how to move forward,” said Nick Fricano, president and CEO of Healthfuse.

To register for the live panel please visit: https://go.beckershospitalreview.com/the-road-to-recovery-4-rcm-leaders-on-the-best-strategies-to-survive-and-thrive-amid-the-pandemic-and-beyond

About Healthfuse

Healthfuse works with 150+ hospitals and health systems to provide revenue cycle vendor management services that reduce cost and increase the collection performance of revenue cycle vendors. Its automated auditing solution for all hospital account collection provides clients with a 24/7 approach to improving the efficiency of all vendor functions and processes by eliminating variability. Healthfuse guides hospitals and health systems as they create a viable, sustainable revenue cycle vendor management office that increases outputs and saves money. Find us here: https://healthfuse.com Follow us here: LinkedIn, Twitter

Share article on social media or email:



Six Board-Certified Reproductive Medicine Specialists at RMA-NJ Have Been Reviewed & Approved By NJ Top Docs For 2020


Reproductive Medicine Associates of NJ

Reproductive Medicine Associates of NJ

Dr. Kathleen H. Hong, Dr. Marcus Jurema, Dr. Leo Doherty, Dr. Shefali M. Shastri, Dr. Micheline Chu, and Dr. Susan L. Treiser of the Reproductive Medicine Associates of NJ have been reviewed and approved by NJ Top Docs for 2020.

Dr. Kathleen Hong is a board certified Reproductive Endocrinologist Infertility specialist and an Obstetrician and Gynecologist. Her research interests include embryo culture in the IVF laboratory, comprehensive chromosome screening (CCS), endometrial synchrony, and heritable genetic disorders.

Dr. Marcus Jurema is a board certified Reproductive Endocrinologist and an Obstetrician and Gynecologist. His areas of clinical expertise include assisted reproductive technologies, recurrent pregnancy loss/implantation failure, ovarian reserve issues, fertility preservation, third-party reproduction and reproductive surgery

Dr. Leo Doherty is a board certified Reproductive Endocrinologist Infertility specialist and an Obstetrician and Gynecologist. His areas of expertise include improving infertility diagnosis and treatment, particularly in the areas of recurrent pregnancy loss, uterine fibroids, embryo and oocyte cryopreservation, uterine anomalies, and minimally invasive endoscopic and robotic-assisted surgeries.

Dr. Shefali Shastri is a board certified Reproductive Endocrinologist and an Obstetrician and Gynecologist. She has extensive experience in the field of in vitro fertilization and has a particular interest and expertise in genetic disorders, preimplantation genetic diagnosis, diminished ovarian reserve, fertility preservation and egg freezing.

Dr. Micheline Chu is a board certified Reproductive Endocrinologist Infertility Specialist and an Obstetrician and Gynecologist. Dr. Chu’s areas of specialty include polycystic ovarian syndrome (PCOS), male infertility, and non-traditional family building.

Dr. Susan Treiser is a board certified Reproductive Endocrinologist and an Obstetrician and Gynecologist. Her areas of specialty include improving infertility diagnosis and treatment, particularly in the areas of third party reproduction, gestational surrogacy, egg donation, and reproductive ethics.

Dr. Melissa C. Yih is a board certified Reproductive Endocrinologist. Her areas of specialty include improving infertility diagnosis and treatment, particularly in the areas of fertility preservation for patients diagnosed with cancer (oncology), adolescent gynecology and gestational surrogacy.

To learn more about these NJ Top Docs, please visit: https://njtopdocs.com/nj-doctors/reproductive-medicine-associates/

—-

About Us

NJ Top Docs is a comprehensive, trusted and exclusive healthcare resource featuring reviewed and approved Top Doctors and Dentists in New Jersey online in an easy to use format. NJ Top Docs only reviews and approves providers based on merit after they have been extensively vetted.

NJ Top Docs is a division of USA Top Docs which allows patients to meet providers online before making their appointment.

For more information, please click here to contact us or visit http://www.NJTopDocs.com.

You can also follow us on Facebook, Twitter, & Instagram.

Share article on social media or email:



Blue Cross NC, Caravan Health Collaborate to Expand Blue Premier to Community and Rural Hospitals for Better Quality, Lower Costs


“We’re excited to team up with community health systems in North Carolina to provide robust primary care and comprehensive accountability for their patients,” said Tim Gronniger, Caravan Health CEO and president.

Blue Cross and Blue Shield of North Carolina (Blue Cross NC) and Caravan Health are working together to support the expansion of Blue Premier, Blue Cross NC’s value-based care program, to more areas of the state. The two companies will establish a new accountable care organization (ACO) that will work with community and rural hospitals to bring the benefits of value-based care to their communities.

The ACO will enable more North Carolina health systems to collaborate with Blue Cross NC and Caravan to provide high-quality, cost-effective care as part of Blue Premier. Under Blue Premier, participating providers and Blue Cross NC are jointly accountable for meeting quality and cost measures. The ACO will bring the benefits of value-based care for patients – including improved quality and better-coordinated care – to North Carolinians who don’t live near a hospital already in Blue Premier.

Hospitals and doctors in rural areas already play a significant role in improving health and coordinating care for their patients. The new ACO will help providers better manage and treat chronic conditions, share in the cost savings through value-based care, and move to a more sustainable financial model than traditional fee-for-service health care – potentially even helping them stay in business following the financial distress caused by COVID-19.

“Extending value-based care through Blue Premier is an important next step in supporting community and rural hospitals, especially as the pandemic has exposed the flaws of fee-for-service,” said Von Nguyen, MD, Blue Cross NC chief medical officer effective Nov. 1, 2020. “Caravan Health will be an essential part of making the benefits of value-based care available to more Blue Cross NC members through access to better, more affordable care.”

“We’re excited to team up with community health systems in North Carolina to provide robust primary care and comprehensive accountability for their patients,” said Tim Gronniger, Caravan Health CEO and president. “The opportunity to align efforts across multiple lines of business dramatically reduces the cost of change for providers, and I thank the team at Blue Cross NC for their foresight in how they’ve designed Blue Premier. Our team is digging in and looking forward to working side-by-side with providers in North Carolina.”

Improving Rural Health

Community and rural providers have seen challenges in adopting value-based care. The smaller population and gaps in technology can make it difficult to achieve the scale needed to show quality improvements and cost reductions. In North Carolina, with an estimated 28 percent of the state’s population living in areas deemed rural by the U.S. Census Bureau, many residents face shortages of medical providers in their communities. About 26 percent of the providers in Blue Cross NC’s network are in rural areas.

The ACO from Blue Cross NC and Caravan will help address these challenges. Providers will have access to Caravan’s methodologies and resources to help them measure and improve quality. These resources include enhanced data analytics, patient engagement technologies and accountability tools, and on-the-ground support from a regional team.

How Blue Premier Works

Blue Premier is one of the most rapid and comprehensive shifts to value-based care in the nation by any health plan. Under value-based care, provider pay is based on quality of care, not on the quantity of procedures, tests and appointments performed.

Blue Premier agreements cover multiple years and build toward shared financial risk between Blue Cross NC and providers, which sets Blue Premier apart from other value-based care arrangements. Eight of North Carolina’s largest health systems, plus more than 200 independent primary care practices, already are in Blue Premier, and future expansion will take value-based care to more areas of the state. Providers in Blue Premier collaborated with Blue Cross NC to generate an estimated $153 million in cost savings, quality improvements and a slowdown in the rate of spending on health care in 2019, the program’s first year.

How Caravan Health Works

In 2018, Caravan Health pioneered its collaborative ACO model to help providers earn strong, predictable results in the Medicare Shared Savings Program. Larger size is critical to create the scale needed for ACO success. The new health system participants will join a Caravan family of more than 250 health systems, 26,000 clinicians, and over 585,000 attributed Medicare lives. Caravan ACOs lead the nation each year, returning more than $108 million in total shared savings to providers and saving Medicare more than $191 million since 2015 while delivering high scores for quality.

In North Carolina, providers in the Blue Premier ACO will mitigate their risk through Caravan’s risk-sharing solution, which focuses on practice transformation and achieving quality goals.

The Caravan Health and Blue Cross NC teams plan to launch the ACO in January 2021. North Carolina hospitals interested in participating may contact a Caravan Health representative to learn more at caravanhealth.com/contact.

About Blue Cross and Blue Shield of North Carolina

Blue Cross and Blue Shield of North Carolina (Blue Cross NC) is committed to making health care better, simpler, and more affordable. We have been driving better health in North Carolina since 1933, working to tackle our communities’ greatest health challenges. Blue Cross NC serves its customers and communities of more than 3.8 million members, including approximately 1.1 million on behalf of other Blue Plans. Visit Blue Cross NC online at http://www.bluecrossnc.com.

About Caravan Health

Caravan Health helps providers make accountable care work regardless of their size, location, history, or demographics. Caravan gives community health systems and providers a way to create more scale, drive more change, and generate more revenue. The 250+ health systems who have turned to Caravan achieved single-year savings greatly exceeding the national average. Health systems and providers across the country are using our proven population health programs to ensure better outcomes for their patients every day. With Caravan Health, now the numbers work. For more information visit http://www.caravanhealth.com.

###

Share article on social media or email:

CURIS System Wins METRO’S Innovative Solutions Award for Fight Against COVID on Buses & Motorcoaches


The portable CURIS Decontamination System for use on buses and motorcoaches

The portable CURIS Decontamination System for use on buses and motorcoaches against COVID-19 and more

Knowing that a hospital-grade disinfection process is being utilized on our coaches, and that the hydrogen peroxide mist solution reaches virtually everywhere is a huge comfort to our passengers.

CURIS System is proud to announce today that is has been awarded the 2020 Innovative Solutions Award for Safety by METRO Magazine for its pulse fogging system that fights SARS-CoV-2 (COVID-19). When the novel coronavirus hit the transportation industry, some companies scrambled to find solutions to help keep drivers safe and routes operational. Traditional cleaning methods often miss areas, and disinfectants that kill 99.9% of germs can still leave up to 1,000 harmful organisms behind on the surface. This was once considered acceptable, but after the pandemic hit that was no longer the case.

Portland, Oregon’s TriMet and N.Y. motorcoach operator Hampton Jitney tapped CURIS System’s hydrogen peroxide fog to revolutionize their disinfection practices and cleaning protocols, changing expectations of germ safety from attempts to “just clean better” to an achievable, measurable kill of 99.9999% of dangerous germs*. TriMet uses the CURIS device daily on every piece of equipment to make sure each and every day they start out with a fresh, clean and safe piece of equipment.

“We’re very pleased that our transportation customers have been recognized for their proactive initiatives to increase the safety and cleanliness of their vehicles with the safest and most effective pulse system on the market today,” said Frances Grinstead, CEO of CURIS System. “As the CARES Act for transportation companies is set to expire on November 1st, we have ramped up our production and delivery to make sure any transport company that is making safety a priority has access to the CURIS System.”

The Coronavirus Aid, Relief, and Economic Security (CARES) Act provides $25 billion to transit agencies to help to prevent, prepare for and respond to the COVID-19 pandemic. CURIS’ sporicidal disinfectant is a hospital-grade, EPA-registered low-level 7% hydrogen peroxide (EPA Reg. No. 93324-1) with a 99.9999% efficacy on the hardest to kill germs* in a tri-part soil load. The hydrogen peroxide decomposes to water and oxygen leaving no harmful residues.

“Knowing that a hospital-grade disinfection process is being utilized on our coaches, and that the hydrogen peroxide mist solution reaches virtually everywhere is a huge comfort to our passengers,” said Andrew Lynch, vice president at Hampton Jitney. “Adding the CURIS fogging system as a part of our sanitizing protocols provides us with a gold standard solution for the COVID-19 era.”

Using the CURoxide™ Hydrogen Peroxide blend, CURIS is the first portable, hydrogen peroxide-based fogging system capable of disinfecting a room or enclosed area via patented pulse technology, and the most efficacious in protecting passengers against COVID-19 and other infectious disease. CURoxide is the only pulse fogging system included on the EPA’s List-N for efficacy against SARS-CoV-2 (COVID-19) and has shown to be 99.9999% effective in killing the most resistant pathogens, while equally as important proving safe to administer and leaving behind no toxic or damaging residues. Staff easily place the portable, suitcase-sized CURIS fogging device into the bus and use an app to control the fogger from a safe location. While the bus quickly fills with germ-killing fog, staff move on to other tasks and use the app to monitor the treatment in progress. When fogging is done, doors are opened for a quick airing out and re-entry. The healthy bus is ready for use and a report of the treatment is saved for future planning and as proof of disinfection.

The CURIS Decontamination System is designed to effectively work in such environments as:


  • Transportation systems, including buses, airplanes, subways, taxis
  • Emergency Response Operations, including fire stations, police stations
  • Universities
  • Medical facilities, including hospitals, assisted living/long-term care facilities
  • Laboratory spaces
  • Sports facilities and gyms
  • Military facilities
  • Research facilities

About CURIS® System

Headquartered in Oviedo, Florida, CURIS System provides the most efficacious germ-killing disinfectant solution with no harmful residues available on the market today. Established in 2014, CURIS’ innovative and patented hydrogen peroxide fogging system has revolutionized portable, high-level disinfection, making hospital-grade decontamination accessible across multiple markets. Its EPA-registered “No Touch” disinfection system uses pulse hydrogen peroxide fog to kill germs and odors. The system is easy to use, portable (roll-behind or hand carry), eco-friendly, non-corrosive and leaves behind NO harmful residues. The CURIS app can be used for remote activation and cloud-based data storage for optimal tracking, management and reporting. For more information, please visit http://www.curissystem.com

*kills 99.9999% of c.diff in a tri-part soil load.

Share article on social media or email:

Kaden Health Announces Strategic Investment by Magellan Health


Kaden Health, Inc. (Kaden) announced today that Magellan Health, Inc. (NASDAQ: MGLN) has made a strategic minority equity investment in the New York-based digital behavioral health company. Through the collaboration, Kaden’s proprietary behavioral telehealth program and platform will be provided to Magellan’s customers, members and patients as well as providers.

Kaden’s advanced technologies position the company as a prime enabler for Magellan in providing behavioral health services at scale and virtually – a key consideration given the COVID-19 epidemic which has only accelerated the need to increase access to effective, evidence-based mental health services. Kaden’s platform – initially applied for the treatment of patients with opioid use disorder and currently available in New Jersey, New York and New Hampshire – brings important capabilities to Magellan that will enhance interactions with members, including collaborative care.

“We are pleased and excited to collaborate with Magellan as Kaden continues to develop and implement advanced technologies and clinical programs supporting those in need of behavioral health support and treatment for substance use disorders,” said Dave Henderson, co-founder and CEO of Kaden. “Both the investment and the business relationship magnify our ability to make access to treatment possible wherever people may be, and to help providers significantly enhance their practices with our purpose-built behavioral telehealth platform.”

“As a leading independent payer services company, Magellan Health is driving innovation into the behavioral health market through the acceleration of digital capabilities that will enhance the patient experience across the care continuum,” said Kenneth Fasola, Chief Executive Officer of Magellan Health. “A tremendous need exists to bring virtual behavioral health solutions to members, and the COVID-19 pandemic has only heightened this need. Our relationship with Kaden will allow us to integrate digital features into new models of behavioral healthcare, demonstrating our ability to offer disruptive, comprehensive and integrated complex care services and insights to our members and clients.”

Kaden delivers its Virtual Medication Assisted Treatment (vMAT) program through its network of affiliated providers throughout the country. The Kaden vMAT program is a fully integrated approach to treating those suffering from opioid use disorder based on the gold standard of Medication Assisted Treatment and leveraging Kaden’s advanced, proprietary virtual technology, which provides a convenient, intuitive and data-driven treatment path for patients. Kaden also makes its HIPAA-compliant behavioral telehealth platform available directly to non-affiliated providers as a stand-alone tailored solution which can be quickly and seamlessly implemented to provide material benefit when compared to the use of general videoconferencing or generic telehealth platforms.

“This investment by Magellan supports and affirms our goal to provide unfettered access to populations in need of treatment,” said Aran Ron, M.D, co-founder and Head of Clinical Innovation at Kaden. “This collaboration helps further our vision to fundamentally transform how effective behavioral health treatments are delivered through the insight and transparency achieved through Kaden’s artificial intelligence, emotional analytics, and real-time reporting, all of which are industry-firsts.”

Kaden’s coordinated approach to vMAT is centered, from the first visit with a medical professional through all succeeding virtual visits and therapy, on the Kaden Technology Platform. This leading-edge intuitive interface allows the patient, therapist, medical prescriber, and the advocate all to communicate and collaborate in ways that ultimately help the patient to reclaim a healthy, productive lifestyle.

After the first visit with a prescriber, a patient can then attend all following medical and therapy appointments using any smartphone, tablet, or PC with an internet connection from the comfort of their homes or any convenient and private location.

Match Point Partners LLC led by Brad Burkett, Managing Partner, acted as financial advisor to Kaden in this transaction.

Kaden Health is a portfolio company of Leverage Health Solutions, which has been engaged since 2018.

About Kaden:

Based in New York City, Kaden is a data-driven digital behavioral health services company dedicated to addressing strategic marketplace issues with a focus on developing advanced technologies as well as innovative service offerings and products that reduce costs, improve quality, encourage engagement and produce better outcomes. Kaden’s first product tackles the opioid addiction crisis by positively influencing human behavior and making advanced technologies and proven treatments accessible to all. Kaden was founded by Dave Henderson, Aran Ron, M.D. and Steve Kessler in 2018. For more information, visit http://www.kadenhealth.com or call 888-88-KADEN.

Company Contact:

Kaden Marketing and Public Relations: Marc Warner (marcw@kadenhealth.com)

Share article on social media or email: